Mike Yee

Graig Suvannavejh × Mike Yee × Eric Schmidt

Biotech is up 7.4% YTD versus the S&P 500 down 4%, as Q1 delivered a record first quarter for public-company M&A: nine deals totaling $32B.Biogen’s $5.6B Apellis acquisition paid a 140% premium to address a potential $1.5B Ocrevus royalty shortfall in 2029–2030, but Alexion and Regeneron Phase 3 GA readouts later this year could test the economics.

Mike Yee × Eric Schmidt × Matt Gline × Yaron Werber

Biotech posted its strongest IPO quarter in four years, with $2B of Q1 IPOs and a $2.5B run rate.Roivant’s Moderna settlement could reach $2.25B, with $950M cash in July and up to $1.3B tied to the §1498 appeal.Paying the contingent amount could leave roughly “two and change” years of cash, while GLP-1 orals broaden a $100B market and threaten consumer categories.

Chris Garabedian × Paul Matteis × Mike Yee × Sam Fazeli

JPM 2026 sentiment settled at a healthy seven out of 10, while record financing and cash-rich companies shifted biotech toward a sellers’ market.Generalists are moving from renting the space to wanting to own the group, broadening interest beyond Lilly and AbbVie.Moderna’s March Arbutus trial and Lilly’s 2027 TRAILBLAZER-ALZ 3 readout are catalysts, with patent damages and safety still unresolved.

Chris Garabedian × Josh Schimmer × Nina Kjellson × Mike Yee × Tim Opler

Summit’s PD-1×VEGF bispecific missed overall survival at p=0.0575, sending shares down 25% despite a PFS hit and 20% lower mortality risk in Western patients.Tim Opler sees VEGF×PD-1 becoming oncology’s backbone, while Pfizer’s 3SBio license and Seagen acquisition give it control for ADC combinations.Macro uncertainty favors discounted commercial-stage M&A, and Gilead’s June 19 lenacapavir PDUFA will test FDA functionality.

Daphne Zohar × John Maraganore × Mike Yee × Sam Fazeli × John Crowley

Biotech entered JPM at “five out of 10,” with macro steering capital and Metsera’s obesity IPO testing a discriminating window.J&J’s $14.6 billion Intra-Cellular Therapies acquisition—following $1.22 billion raised and approximately 13× value creation—shows pharma’s appetite for derisked CNS assets, while China’s speed and cost make FDA trial reform a potential catalyst.